Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
A-HYDROCORT vs PROAIR HFA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrocortisone is a corticosteroid hormone that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, inhibit immune response, and regulate metabolism.
Selective beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.
Adrenocortical insufficiency (primary and secondary),Congenital adrenal hyperplasia,Inflammatory conditions (e.g., rheumatoid arthritis, ulcerative colitis),Allergic reactions (severe),Asthma exacerbations,Dermatologic disorders (topical use),Ophthalmic inflammation (ophthalmic use)
Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease,Prevention of exercise-induced bronchospasm
Adrenal insufficiency: oral 20-30 mg/day in divided doses; inflammatory conditions: 5-60 mg/day oral; IV/IM: hydrocortisone sodium succinate 50-100 mg every 4-6 hours.
Two inhalations (90 mcg each) via oral inhalation every 4-6 hours as needed; for prevention of exercise-induced bronchospasm, two inhalations 15-30 minutes before exercise.
Terminal half-life: 1.5-2 hours (cortisol); clinical effect persists 8-12 hours due to glucocorticoid receptor binding
Terminal elimination half-life: 3.8 to 5 hours; clinically, this supports a dosing interval of every 4-6 hours as needed for symptom relief.
Primarily hepatic via CYP3A4 and other CYP450 enzymes, with reduction in the A-ring to inactive metabolites (e.g., tetrahydrocortisol).
Primarily metabolized by catechol-O-methyltransferase (COMT) and to a lesser extent by sulfation; not metabolized by CYP450 enzymes.
Renal (primarily as metabolites, <1% unchanged); biliary/fecal (<5%)
Renal: approximately 72% as unchanged drug and metabolites; fecal: approximately 10%; biliary: minimal.
90-95% bound to corticosteroid-binding globulin (CBG) and albumin
Approximately 94% bound to human serum albumin.
0.5-0.8 L/kg; represents distribution into total body water, higher in obesity
Vd: 1.9 to 2.7 L/kg; this large Vd indicates extensive distribution into tissues, including lung tissue.
Oral: 96% (well absorbed); IM/IV: 100%; topical: minimal systemic absorption (<1% with intact skin)
Inhalation: approximately 10-20% of the administered dose reaches the lungs; the remainder is swallowed and undergoes first-pass metabolism resulting in negligible oral bioavailability.
No specific adjustment required; monitor fluid/electrolytes in severe renal impairment.
No dosage adjustment required for renal impairment.
Dose reduction may be necessary in severe hepatic impairment; caution as metabolism is hepatic.
No dosage adjustment required for hepatic impairment.
Doses are weight-based; for adrenal insufficiency: 0.5-0.75 mg/kg/day in divided doses; for anti-inflammatory: 0.5-10 mg/kg/day.
Children 4-11 years: Two inhalations (90 mcg each) via oral inhalation every 4-6 hours as needed; for exercise-induced bronchospasm, two inhalations 15-30 minutes before exercise. Children <4 years: Safety and efficacy not established.
Use lowest effective dose; monitor for osteoporosis, hypertension, and glucose intolerance.
No specific dose adjustment; use with caution due to potential for decreased renal function and increased sensitivity to beta-agonists.
None.
Not applicable; no black box warning.
Immunosuppression and increased infection risk,Adrenal suppression with prolonged use,Cushing's syndrome with chronic use,Osteoporosis with long-term use,GI perforation risk in inflammatory bowel disease,Growth suppression in children,Fetal harm (category C),Ocular effects (cataracts, glaucoma),Fluid and electrolyte disturbances
Paradoxical bronchospasm may occur,Cardiovascular effects: increased heart rate, blood pressure, or ECG changes,Immediate hypersensitivity reactions,Potentially severe hypokalemia,May exacerbate diabetes and ketoacidosis
Systemic fungal infections,Hypersensitivity to hydrocortisone or any component,Administration of live or live-attenuated vaccines (relative),Herpes simplex keratitis (topical ophthalmic use),Peptic ulcer disease (relative),Uncontrolled hypertension (relative)
Hypersensitivity to albuterol or any component of the formulation
No specific food interactions. However, high-sodium foods may exacerbate fluid retention; a low-sodium diet is recommended if edema occurs. Grapefruit juice does not significantly affect hydrocortisone. Avoid alcohol due to additive gastric irritation.
No significant food interactions. Avoid caffeine and stimulants as they may increase cardiovascular side effects (tachycardia, palpitations). No dietary restrictions required.
Hydrocortisone is a corticosteroid. Use during first trimester is associated with increased risk of oral clefts (odds ratio 1.5-3.0). Second and third trimester use may cause fetal adrenal suppression, growth restriction, and premature birth. Risk of premature rupture of membranes and intrauterine growth restriction increases with prolonged use.
FDA Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, albuterol sulfate caused fetal malformations (cleft palate, limb defects) at doses 0.4-1.2 times the maximum human daily inhalation dose. Risk cannot be ruled out; use only if potential benefit justifies potential risk. For trimester-specific risks: first trimester: potential for orofacial clefts and limb defects; second/third trimesters: risk of maternal tachycardia and hypoglycemia in neonate; labor inhibition near term; possible neonatal transient hypoglycemia.
Hydrocortisone is excreted into breast milk in low concentrations. M/P ratio approximately 0.4-1.0. Doses up to 20 mg/day are considered compatible with breastfeeding. Higher doses may suppress infant adrenal function; monitor infant for growth and adrenal suppression.
Albuterol is excreted into human breast milk in small amounts (M/P ratio not established). No reported adverse effects in nursing infants. Use with caution in lactating women; benefit of breastfeeding should outweigh potential risk to infant. Monitor infant for signs of beta-adrenergic stimulation (tachycardia, irritability).
Due to increased clearance and protein binding changes, doses may need to be increased by 50-100% in the second and third trimesters. Monitor clinical response and adjust dose accordingly. Stress doses (e.g., 50-100 mg IV) should be given during labor and delivery.
No specific dose adjustment required; however, pharmacokinetic changes in pregnancy (increased volume of distribution, increased clearance) may theoretically require dose frequency adjustment. Use the lowest effective dose and monitor clinical response. No dose adjustment needed based on current evidence.
For acute adrenal insufficiency, give IV bolus of 100 mg hydrocortisone followed by 100 mg every 8 hours. Taper to oral replacement over days. In septic shock, stress-dose hydrocortisone (200 mg/day) may be used if vasopressor-dependent. Monitor for hyperglycemia, hypokalemia, and immunosuppression. Abrupt discontinuation can cause adrenal crisis.
Primarily a rescue inhaler for acute asthma exacerbations. Not for maintenance therapy. Shake well before each use. Prime with 3 test sprays when new or not used for >2 weeks. Use spacer device to improve lung deposition and reduce oropharyngeal side effects. Monitor for paradoxical bronchospasm. Tachycardia and hypokalemia can occur with overuse. Replace canister after 200 actuations.
Take exactly as prescribed; do not stop suddenly without doctor's guidance.,Carry a medical alert card or bracelet indicating you take hydrocortisone.,Report signs of adrenal crisis: severe weakness, dizziness, nausea, vomiting, abdominal pain.,During illness or stress (e.g., surgery, infection), dose may need temporary increase; contact your doctor.,Avoid live vaccines during therapy.,Monitor for weight gain, swelling, mood changes, or high blood sugar symptoms (increased thirst, urination).
Use only as needed for shortness of breath, wheezing, or chest tightness.,Do not use more frequently than prescribed; overuse can lead to serious side effects.,Shake the inhaler vigorously for 5 seconds before each spray.,Prime the inhaler by releasing 3 test sprays into the air before first use or if not used for more than 2 weeks.,Use a spacer device if prescribed to improve medication delivery to the lungs.,Rinse mouth with water after each use to prevent thrush (oral fungal infection).,Seek immediate medical help if symptoms worsen or if you need more than 2 puffs per week for relief.,Store at room temperature away from moisture and heat; do not freeze.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about A-HYDROCORT vs PROAIR HFA, answered by our medical review team.
A-HYDROCORT is a Corticosteroid that works by Hydrocortisone is a corticosteroid hormone that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, inhibit immune response, and regulate metabolism.. PROAIR HFA is a Beta-2 Agonist Bronchodilator that works by Selective beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between A-HYDROCORT and PROAIR HFA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of A-HYDROCORT is: Adrenal insufficiency: oral 20-30 mg/day in divided doses; inflammatory conditions: 5-60 mg/day oral; IV/IM: hydrocortisone sodium succinate 50-100 mg every 4-6 hours.. The standard adult dose of PROAIR HFA is: Two inhalations (90 mcg each) via oral inhalation every 4-6 hours as needed; for prevention of exercise-induced bronchospasm, two inhalations 15-30 minutes before exercise.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between A-HYDROCORT and PROAIR HFA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. A-HYDROCORT is classified as Category C. Hydrocortisone is a corticosteroid. Use during first trimester is associated with increased risk of oral clefts (odds ratio 1.5-3.0). Second and third trimester use may cause fetal. PROAIR HFA is classified as Category C. FDA Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, albuterol sulfate caused fetal malformations (cleft palate, limb defects) at dos. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.